Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple-dose safety, PK/PD, food-effect, and relative bioavailability study of AS-0871 in healthy adults
NL-OMON53402Phase 1Completed
- Sponsor
- Carna Biosciences, Inc.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sofnobrutinib in urticaria, rheumatoid arthritis (RA), allergy and 1 more (6 arms), sponsored by Carna Biosciences, Inc. Started Dec 2021; status: completed.
02
Drugs
sofnobrutinib
03
Conditions
urticariarheumatoid arthritis (RA)allergyautoimmune disease
Beyond the preview
Go deeper on NL-OMON53402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53402.